Allarity Therapeutics (ALLR) News Today → What’s Really Next for America… (From Porter & Company) (Ad) Free ALLR Stock Alerts $0.80 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 2:58 AM | americanbankingnews.comAllarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 110.5% in AprilMay 7, 2024 | globenewswire.comAllarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common StockMay 6, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | finance.yahoo.comAllarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 6, 2024 | globenewswire.comAllarity Therapeutics Exceeds Nasdaq's Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1May 2, 2024 | msn.comWhy Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?May 2, 2024 | benzinga.comNasdaq Jumps Over 100 Points; Kellanova Posts Upbeat ResultsMay 2, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 39% Today?May 2, 2024 | finance.yahoo.comAllarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerMay 2, 2024 | globenewswire.comAllarity Therapeutics' Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian CancerApril 29, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 29, 2024 | globenewswire.comAllarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price RequirementApril 17, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)April 17, 2024 | finance.yahoo.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 17, 2024 | globenewswire.comAllarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)April 12, 2024 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 41% Today?April 9, 2024 | marketbeat.comTrading was temporarily halted for "ALLR" at 07:04 PM with a stated reason of "News pending."April 4, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Announces 1-for-20 Reverse Stock SplitApril 4, 2024 | msn.comAllarity Therapeutics to implement 1-for-20 reverse stock splitApril 4, 2024 | globenewswire.comAllarity Therapeutics Announces 1-for-20 Reverse Stock SplitMarch 27, 2024 | globenewswire.comAllarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian CancerMarch 25, 2024 | globenewswire.comAllarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)March 8, 2024 | finanznachrichten.deAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateMarch 8, 2024 | benzinga.comAllarity Therapeutics: Q4 Earnings InsightsMarch 8, 2024 | globenewswire.comAllarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business UpdateFebruary 28, 2024 | globenewswire.comAllarity Therapeutics to Present at Biomarkers 2024February 23, 2024 | benzinga.comAllarity Therapeutics Stock (NASDAQ:ALLR), Short Interest ReportFebruary 23, 2024 | benzinga.comAllarity Therapeutics Stock (NASDAQ:ALLR) Dividends: History, Yield and DatesFebruary 2, 2024 | bizjournals.comBoston biotech loses Novartis drug license agreement for nonpaymentFebruary 2, 2024 | msn.comAllarity Therapeutics’ Licensing Agreement with Novartis TerminatedDecember 12, 2023 | markets.businessinsider.comAllarity Therapeutics CEO James Cullem Steps DownDecember 12, 2023 | finance.yahoo.comAllarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive AdvisorDecember 7, 2023 | finance.yahoo.comALLR: Stenoparib Clinical UpdateDecember 6, 2023 | seekingalpha.comAllarity stock soars 60% premarket on ovarian cancer therapy resultsDecember 5, 2023 | investorplace.comWhy Is Allarity Therapeutics (ALLR) Stock Up 42% Today?December 5, 2023 | markets.businessinsider.comAllarity's Early Phase 2 Stenoparib Data Suggests Encouraging Results In Advanced Ovarian CancerDecember 5, 2023 | finance.yahoo.comAllarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion DiagnosticNovember 10, 2023 | morningstar.comAllarity Therapeutics Inc ALLRNovember 2, 2023 | msn.comAllarity Therapeutics files for $50M mixed shelfOctober 2, 2023 | finance.yahoo.comAllarity Therapeutics to Present at Biomarkers Europe 2023September 14, 2023 | finance.yahoo.comAllarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) TechnologyAugust 31, 2023 | benzinga.comThinking about buying stock in Allarity Therapeutics, Better Home & Finance Holding, Top KingWin, Axcella Health, or Metatron Apps?August 31, 2023 | benzinga.comWhat's Going On With Allarity Therapeutics Stock?August 31, 2023 | markets.businessinsider.comPre-market Movers: ICCT, NCNC, ALLR, LYRA, MYNZ…August 31, 2023 | nasdaq.comAllarity's DRP Companion Diagnostic For Dovitinib Earns Peer-Reviewed Spotlight, Stock JumpsAugust 30, 2023 | finance.yahoo.comPLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for DovitinibJuly 31, 2023 | msn.comWhy is Allarity Therapeutics Stock Trading Higher Today?July 31, 2023 | finance.yahoo.comAllarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion DiagnosticsJuly 12, 2023 | finance.yahoo.comALLR: IXEMPRA Clinical UpdateJuly 7, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. ALLR Media Mentions By Week ALLR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼0.410.57▲Average Medical News Sentiment ALLR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼51▲ALLR Articles Average Week Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PainReform News 180 Life Sciences News Qualigen Therapeutics News InMed Pharmaceuticals News PaxMedica News Clearmind Medicine News NeuBase Therapeutics News Bio-Path News Galmed Pharmaceuticals News Lucy Scientific Discovery News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
